These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33955235)

  • 1. Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues.
    Ferranti M; Cicogna GT; Messina F; Alaibac M
    Immunotherapy; 2021 Jul; 13(10):795-798. PubMed ID: 33955235
    [No Abstract]   [Full Text] [Related]  

  • 2. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
    Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of immune checkpoint inhibitor-related dermatologic adverse events.
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune-related adverse events: what we've learned and where we're heading.
    Badran YR; Leet DE; Dougan M
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):727-730. PubMed ID: 32726153
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis.
    Park R; Lopes L; Saeed A
    Immunotherapy; 2020 Nov; 12(16):1183-1193. PubMed ID: 32878511
    [No Abstract]   [Full Text] [Related]  

  • 9. Supportive care for patients undergoing immunotherapy.
    Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
    Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
    J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
    Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
    Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
    Khan OF; Monzon J
    Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events.
    Ashoori MD; Suzuki K; Tokumaru Y; Ikuta N; Tajima M; Honjo T; Ohta A
    Front Immunol; 2020; 11():618711. PubMed ID: 33584713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
    Correale P; Saladino RE; Giannarelli D; Sergi A; Mazzei MA; Bianco G; Giannicola R; Iuliano E; Forte IM; Calandruccio ND; Falzea AC; Strangio A; Nardone V; Pastina P; Tini P; Luce A; Caraglia M; Caracciolo D; Mutti L; Tassone P; Pirtoli L; Giordano A; Tagliaferri P
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
    Bocanegra A; Blanco E; Fernandez-Hinojal G; Arasanz H; Chocarro L; Zuazo M; Morente P; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
    Hajem S; Ederhy S; Champiat S; Troalen F; Nolin-Lapalme A; Berhoune M; Cauquil C; Martin-Romano P; Baldini C; Laparra A; Vuagnat P; Hollebecque A; Mateus C; Besse B; Naltet C; Robert C; Marabelle A; Massard C; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 157():383-390. PubMed ID: 34571335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models.
    Park BC; Stone CA; Dewan AK; Johnson DB
    Immunol Allergy Clin North Am; 2022 May; 42(2):285-305. PubMed ID: 35469619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Keiser MF; Patel AB; Altan M
    Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.